CD3+ B Cells and CD20+ T Cells in Multiple Sclerosis
Researchers identified CD3+ B cells and CD20+ T cells resulting from interactions between T and B cells in a laboratory setting related to MS. These CD20+ T cells were found to be present in cerebrospinal fluid, showing signs of cytotoxic activity and reactivity to myelin antigens, and responding to treatment that removed certain lymphocytes.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This study enhances our understanding of immune cell interactions in MS, especially the potential roles of CD20+ T cells in the disease process, which may influence future research directions into immune therapies.
What this does not prove
The findings are based on laboratory analyses, not clinical trials, so they cannot confirm treatment effectiveness or outcomes in human subjects.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-01
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceT-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis. ↗DOI: 10.1073/pnas.2605806123
Supporting passages (3)
publication datePublication date: 2026-10-01
findingsTitle: T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.
limitationsTitle: T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.